Annual EBITDA
-$16.98 M
+$36.89 M+68.48%
31 December 2023
Summary:
Rigel Pharmaceuticals annual earnings before interest, taxes, depreciation & amortization is currently -$16.98 million, with the most recent change of +$36.89 million (+68.48%) on 31 December 2023. During the last 3 years, it has risen by +$10.70 million (+38.66%). RIGL annual EBITDA is now -143.21% below its all-time high of $39.30 million, reached on 31 December 2010.RIGL EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly EBITDA
$15.09 M
+$13.48 M+836.23%
30 September 2024
Summary:
Rigel Pharmaceuticals quarterly earnings before interest, taxes, depreciation & amortization is currently $15.09 million, with the most recent change of +$13.48 million (+836.23%) on 30 September 2024. Over the past year, it has increased by +$18.59 million (+531.08%). RIGL quarterly EBITDA is now -70.28% below its all-time high of $50.77 million, reached on 30 September 2010.RIGL Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM EBITDA
$13.67 M
+$18.59 M+377.52%
30 September 2024
Summary:
Rigel Pharmaceuticals TTM earnings before interest, taxes, depreciation & amortization is currently $13.67 million, with the most recent change of +$18.59 million (+377.52%) on 30 September 2024. Over the past year, it has increased by +$30.79 million (+179.81%). RIGL TTM EBITDA is now -66.51% below its all-time high of $40.81 million, reached on 31 March 2011.RIGL TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
RIGL EBITDA Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +68.5% | +531.1% | +179.8% |
| 3 y3 years | +38.7% | +177.4% | +253.7% |
| 5 y5 years | +75.7% | +233.4% | +129.8% |
RIGL EBITDA High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -50.5% | +68.5% | at high | +158.0% | at high | +117.2% |
| 5 y | 5 years | -50.5% | +75.7% | -64.1% | +158.0% | at high | +117.2% |
| alltime | all time | -143.2% | +87.0% | -70.3% | +139.4% | -66.5% | +110.3% |
Rigel Pharmaceuticals EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $15.09 M(+836.2%) | $13.67 M(-377.5%) |
| June 2024 | - | $1.61 M(-127.0%) | -$4.92 M(-55.1%) |
| Mar 2024 | - | -$5.97 M(-303.4%) | -$10.98 M(-35.3%) |
| Dec 2023 | -$16.98 M(-68.5%) | $2.94 M(-183.9%) | -$16.98 M(-0.8%) |
| Sept 2023 | - | -$3.50 M(-21.2%) | -$17.13 M(-45.8%) |
| June 2023 | - | -$4.44 M(-62.9%) | -$31.60 M(-20.7%) |
| Mar 2023 | - | -$11.97 M(-528.9%) | -$39.84 M(-26.0%) |
| Dec 2022 | -$53.87 M(+377.3%) | $2.79 M(-115.5%) | -$53.87 M(-30.6%) |
| Sept 2022 | - | -$17.97 M(+41.7%) | -$77.66 M(-1.9%) |
| June 2022 | - | -$12.69 M(-51.2%) | -$79.20 M(-0.1%) |
| Mar 2022 | - | -$26.00 M(+23.8%) | -$79.28 M(+602.4%) |
| Dec 2021 | -$11.29 M(-59.2%) | -$21.00 M(+7.6%) | -$11.29 M(+26.9%) |
| Sept 2021 | - | -$19.51 M(+52.7%) | -$8.89 M(+200.3%) |
| June 2021 | - | -$12.77 M(-130.4%) | -$2.96 M(-59.1%) |
| Mar 2021 | - | $41.99 M(-325.8%) | -$7.25 M(-73.8%) |
| Dec 2020 | -$27.68 M(-58.0%) | -$18.60 M(+37.0%) | -$27.68 M(+7.4%) |
| Sept 2020 | - | -$13.58 M(-20.4%) | -$25.78 M(+9.6%) |
| June 2020 | - | -$17.06 M(-179.1%) | -$23.51 M(-12.5%) |
| Mar 2020 | - | $21.56 M(-229.1%) | -$26.89 M(-59.2%) |
| Dec 2019 | -$65.88 M(-5.7%) | -$16.69 M(+47.5%) | -$65.88 M(+43.9%) |
| Sept 2019 | - | -$11.32 M(-44.6%) | -$45.79 M(-21.2%) |
| June 2019 | - | -$20.43 M(+17.2%) | -$58.08 M(-8.7%) |
| Mar 2019 | - | -$17.43 M(-614.1%) | -$63.60 M(-10.2%) |
| Dec 2018 | -$69.89 M(-9.9%) | $3.39 M(-114.4%) | -$70.79 M(-28.2%) |
| Sept 2018 | - | -$23.61 M(-9.0%) | -$98.66 M(+6.3%) |
| June 2018 | - | -$25.95 M(+5.4%) | -$92.79 M(+7.8%) |
| Mar 2018 | - | -$24.62 M(+0.6%) | -$86.07 M(+11.0%) |
| Dec 2017 | -$77.53 M(+23.0%) | -$24.48 M(+38.0%) | -$77.53 M(+12.9%) |
| Sept 2017 | - | -$17.74 M(-7.7%) | -$68.69 M(+1.5%) |
| June 2017 | - | -$19.23 M(+19.6%) | -$67.70 M(+9.4%) |
| Mar 2017 | - | -$16.08 M(+2.8%) | -$61.86 M(-1.9%) |
| Dec 2016 | -$63.03 M(+25.3%) | -$15.64 M(-6.6%) | -$63.03 M(+5.4%) |
| Sept 2016 | - | -$16.75 M(+25.1%) | -$59.80 M(+20.7%) |
| June 2016 | - | -$13.39 M(-22.4%) | -$49.53 M(-0.4%) |
| Mar 2016 | - | -$17.24 M(+39.0%) | -$49.74 M(-1.1%) |
| Dec 2015 | -$50.30 M(-43.4%) | -$12.41 M(+91.1%) | -$50.30 M(-15.8%) |
| Sept 2015 | - | -$6.49 M(-52.2%) | -$59.76 M(-19.0%) |
| June 2015 | - | -$13.60 M(-23.6%) | -$73.73 M(-13.2%) |
| Mar 2015 | - | -$17.81 M(-18.5%) | -$84.97 M(-4.4%) |
| Dec 2014 | -$88.89 M(+4.3%) | -$21.86 M(+6.8%) | -$88.89 M(+6.7%) |
| Sept 2014 | - | -$20.47 M(-17.6%) | -$83.32 M(-1.4%) |
| June 2014 | - | -$24.83 M(+14.3%) | -$84.46 M(+3.1%) |
| Mar 2014 | - | -$21.73 M(+33.4%) | -$81.89 M(-3.9%) |
| Dec 2013 | -$85.20 M(-12.1%) | -$16.29 M(-24.6%) | -$85.20 M(-9.3%) |
| Sept 2013 | - | -$21.61 M(-2.9%) | -$93.89 M(-3.4%) |
| June 2013 | - | -$22.26 M(-11.1%) | -$97.21 M(-2.0%) |
| Mar 2013 | - | -$25.04 M(+0.2%) | -$99.23 M(+2.4%) |
| Dec 2012 | -$96.94 M | -$24.98 M(+0.2%) | -$96.94 M(+0.0%) |
| Sept 2012 | - | -$24.93 M(+2.7%) | -$96.93 M(+8.3%) |
| June 2012 | - | -$24.27 M(+6.7%) | -$89.53 M(+3.7%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2012 | - | -$22.76 M(-8.8%) | -$86.34 M(+2.8%) |
| Dec 2011 | -$83.99 M(-313.7%) | -$24.96 M(+42.4%) | -$83.99 M(+10.7%) |
| Sept 2011 | - | -$17.54 M(-16.8%) | -$75.85 M(+905.5%) |
| June 2011 | - | -$21.08 M(+3.3%) | -$7.54 M(-118.5%) |
| Mar 2011 | - | -$20.41 M(+21.3%) | $40.81 M(+4.2%) |
| Dec 2010 | $39.30 M(-135.7%) | -$16.82 M(-133.1%) | $39.17 M(+25.2%) |
| Sept 2010 | - | $50.77 M(+86.2%) | $31.29 M(-168.4%) |
| June 2010 | - | $27.27 M(-223.7%) | -$45.73 M(-55.4%) |
| Mar 2010 | - | -$22.05 M(-10.8%) | -$102.46 M(-6.9%) |
| Dec 2009 | -$110.03 M(-15.9%) | -$24.71 M(-5.8%) | -$110.03 M(-3.9%) |
| Sept 2009 | - | -$26.24 M(-10.9%) | -$114.53 M(-9.5%) |
| June 2009 | - | -$29.47 M(-0.5%) | -$126.62 M(-4.1%) |
| Mar 2009 | - | -$29.61 M(+1.4%) | -$132.06 M(+0.9%) |
| Dec 2008 | -$130.85 M(+67.4%) | -$29.21 M(-23.8%) | -$130.85 M(+7.6%) |
| Sept 2008 | - | -$38.33 M(+9.8%) | -$121.56 M(+17.7%) |
| June 2008 | - | -$34.91 M(+22.9%) | -$103.33 M(+16.5%) |
| Mar 2008 | - | -$28.40 M(+42.6%) | -$88.68 M(+13.4%) |
| Dec 2007 | -$78.18 M(+87.8%) | -$19.92 M(-0.8%) | -$78.18 M(+4.6%) |
| Sept 2007 | - | -$20.09 M(-0.9%) | -$74.73 M(+11.5%) |
| June 2007 | - | -$20.27 M(+13.2%) | -$67.04 M(+33.9%) |
| Mar 2007 | - | -$17.90 M(+8.7%) | -$50.05 M(+20.2%) |
| Dec 2006 | -$41.63 M(-10.9%) | -$16.46 M(+32.8%) | -$41.63 M(+19.7%) |
| Sept 2006 | - | -$12.40 M(+278.2%) | -$34.77 M(-3.5%) |
| June 2006 | - | -$3.28 M(-65.4%) | -$36.03 M(-20.1%) |
| Mar 2006 | - | -$9.48 M(-1.3%) | -$45.11 M(-3.5%) |
| Dec 2005 | -$46.74 M(-14.2%) | -$9.61 M(-29.7%) | -$46.74 M(-8.9%) |
| Sept 2005 | - | -$13.66 M(+10.6%) | -$51.32 M(-4.0%) |
| June 2005 | - | -$12.35 M(+11.1%) | -$53.48 M(+0.7%) |
| Mar 2005 | - | -$11.12 M(-21.6%) | -$53.12 M(-2.5%) |
| Dec 2004 | -$54.49 M(+44.7%) | -$14.18 M(-10.4%) | -$54.49 M(+5.8%) |
| Sept 2004 | - | -$15.83 M(+32.0%) | -$51.53 M(+11.9%) |
| June 2004 | - | -$11.99 M(-4.0%) | -$46.05 M(+5.6%) |
| Mar 2004 | - | -$12.49 M(+11.3%) | -$43.60 M(+15.8%) |
| Dec 2003 | -$37.65 M(+20.7%) | -$11.22 M(+8.4%) | -$37.65 M(+13.9%) |
| Sept 2003 | - | -$10.35 M(+8.5%) | -$33.04 M(+4.8%) |
| June 2003 | - | -$9.54 M(+45.8%) | -$31.53 M(+1.7%) |
| Mar 2003 | - | -$6.54 M(-1.0%) | -$31.02 M(-0.5%) |
| Dec 2002 | -$31.19 M(+71.4%) | -$6.61 M(-25.2%) | -$31.19 M(+7.4%) |
| Sept 2002 | - | -$8.84 M(-2.0%) | -$29.05 M(+16.2%) |
| June 2002 | - | -$9.03 M(+34.4%) | -$24.99 M(+13.2%) |
| Mar 2002 | - | -$6.71 M(+50.2%) | -$22.08 M(+21.3%) |
| Dec 2001 | -$18.20 M(+1.4%) | -$4.47 M(-6.5%) | -$18.20 M(-63.0%) |
| Sept 2001 | - | -$4.78 M(-21.7%) | -$49.24 M(+19.7%) |
| June 2001 | - | -$6.11 M(+115.3%) | -$41.13 M(+29.8%) |
| Mar 2001 | - | -$2.84 M(-92.0%) | -$31.68 M(+24.2%) |
| Dec 2000 | -$17.95 M(+76.4%) | -$35.51 M(-1164.5%) | -$25.50 M(-354.8%) |
| Sept 2000 | - | $3.34 M(0.0%) | $10.01 M(+50.0%) |
| June 2000 | - | $3.34 M(0.0%) | $6.67 M(+100.0%) |
| Mar 2000 | - | $3.34 M | $3.34 M |
| Dec 1999 | -$10.17 M | - | - |
FAQ
- What is Rigel Pharmaceuticals annual earnings before interest, taxes, depreciation & amortization?
- What is the all time high annual EBITDA for Rigel Pharmaceuticals?
- What is Rigel Pharmaceuticals annual EBITDA year-on-year change?
- What is Rigel Pharmaceuticals quarterly earnings before interest, taxes, depreciation & amortization?
- What is the all time high quarterly EBITDA for Rigel Pharmaceuticals?
- What is Rigel Pharmaceuticals quarterly EBITDA year-on-year change?
- What is Rigel Pharmaceuticals TTM earnings before interest, taxes, depreciation & amortization?
- What is the all time high TTM EBITDA for Rigel Pharmaceuticals?
- What is Rigel Pharmaceuticals TTM EBITDA year-on-year change?
What is Rigel Pharmaceuticals annual earnings before interest, taxes, depreciation & amortization?
The current annual EBITDA of RIGL is -$16.98 M
What is the all time high annual EBITDA for Rigel Pharmaceuticals?
Rigel Pharmaceuticals all-time high annual earnings before interest, taxes, depreciation & amortization is $39.30 M
What is Rigel Pharmaceuticals annual EBITDA year-on-year change?
Over the past year, RIGL annual earnings before interest, taxes, depreciation & amortization has changed by +$36.89 M (+68.48%)
What is Rigel Pharmaceuticals quarterly earnings before interest, taxes, depreciation & amortization?
The current quarterly EBITDA of RIGL is $15.09 M
What is the all time high quarterly EBITDA for Rigel Pharmaceuticals?
Rigel Pharmaceuticals all-time high quarterly earnings before interest, taxes, depreciation & amortization is $50.77 M
What is Rigel Pharmaceuticals quarterly EBITDA year-on-year change?
Over the past year, RIGL quarterly earnings before interest, taxes, depreciation & amortization has changed by +$18.59 M (+531.08%)
What is Rigel Pharmaceuticals TTM earnings before interest, taxes, depreciation & amortization?
The current TTM EBITDA of RIGL is $13.67 M
What is the all time high TTM EBITDA for Rigel Pharmaceuticals?
Rigel Pharmaceuticals all-time high TTM earnings before interest, taxes, depreciation & amortization is $40.81 M
What is Rigel Pharmaceuticals TTM EBITDA year-on-year change?
Over the past year, RIGL TTM earnings before interest, taxes, depreciation & amortization has changed by +$30.79 M (+179.81%)